Cytokinetics
CYTKCytokinetics is a fully-integrated specialty biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class muscle activators and inhibitors.
Earnings
Next report
Aug 6, 2026 (In 3 weeks)Valuation & ratios
Segments
By product
Competitors
By market cap
By revenue growth
By net margin
Profile
Cytokinetics is a fully-integrated specialty biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class muscle activators and inhibitors. The company leverages its expertise in the cytoskeleton and muscle biology to treat debilitating cardiovascular and neuromuscular diseases. Its core value proposition centers on modulating muscle function and contractility to improve patient healthspan and address high unmet medical needs.
A leader in muscle biology and mechanics, transitioning from a clinical-stage R&D firm to a commercial-stage specialty biopharmaceutical company with the approval of MYQORZO.
Questions, answered.
- What is Cytokinetics's market cap?
- Cytokinetics (CYTK) has a market capitalization of $11.5B and trades on NASDAQ.
- What is Cytokinetics's revenue and profitability?
- Cytokinetics generated $105.8M in trailing twelve-month revenue with a net loss of $829.6M, representing a net margin of -784.0%, with free cash flow of -$548.9M. These figures are based on the Q1 2026 filing.
- Who are Cytokinetics's competitors?
- Cytokinetics's key competitors include Edgewise Therapeutics, Tenaya Therapeutics, Bristol Myers Squibb, and others. These companies compete in similar markets and product categories.
- Who does Cytokinetics partner with?
- Cytokinetics's notable partners include Sanofi, Bayer, Royalty Pharma, and others.
- Where is Cytokinetics headquartered?
- Cytokinetics is headquartered in United States of America and employs approximately 564 people. It has been publicly traded since 2004.
